Drugs / AB-218
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05814536 | May 2023 → Aug 2024 | cancer, hepatobiliary disorder | AnHeart Therapeutics Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AB-218 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05814536 ↗ |
| Action | Inhibit | “oral IDH1 inhibitor” NCT05814536 ↗ |
| Route | Oral | “Take AB-218 orally twice daily” NCT05814536 ↗ |
| Target | IDH1 | “oral IDH1 inhibitor” NCT05814536 ↗ |